DNA epitope vaccine containing complement component C3d enhances anti-amyloid-β antibody production and polarizes the immune response towards a Th2 phenotype

Nina Movsesyan, Mikayel Mkrtichyan, Irina Petrushina, Ted M. Ross, David H. Cribbs, Michael G. Agadjanyan, Anahit Ghochikyan

Research output: Contribution to journalArticle

25 Scopus citations


We have engineered a DNA epitope vaccine that expresses 3 self-B cell epitopes of Aβ42 (3Aβ1-11), a non-self T helper (Th) cell epitope (PADRE), and 3 copies of C3d (3C3d), a component of complement as a molecular adjuvant, designed to safely reduce CNS Aβ. Immunization of mice with 3Aβ1-11-PADRE epitope vaccine alone generated only moderate levels of anti-Aβ antibodies and a pro-inflammatory T helper (Th1 phenotype) cellular immune response. However, the addition of 3C3d to the vaccine construct significantly augmented the anti-Aβ humoral immune response and, importantly, shifted the cellular immune response towards the potentially safer anti-inflammatory Th2 phenotype.

Original languageEnglish (US)
Pages (from-to)57-63
Number of pages7
JournalJournal of Neuroimmunology
Issue number1-2
Publication statusPublished - Dec 15 2008



  • AN-1792
  • Alzheimer's disease
  • Amyloid-beta
  • DNA vaccine
  • Immunotherapy
  • Molecular adjuvant

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology

Cite this